Sabat, Robert
Jemec, Gregor B. E.
Matusiak, Łukasz
Kimball, Alexa B.
Prens, Errol
Wolk, Kerstin
Article History
Accepted: 23 January 2020
First Online: 12 March 2020
Competing interests
: R.S. is a member of Arbeitsgemeinschaft Dermatologische Forschung (ADF; Consortium for Dermatological Research), the German Society of Allergy and Clinical Immunology (DGAKI), the German Society of Immunology (DGfI), the American Association of Immunologists (AAI), the International Psoriasis Council (IPC) and the European Hidradenitis Suppurativa Foundation (EHSF), and is the spokesman of the ADF Psoriasis Group. R.S. has received research grants and scientific awards or honoraria for participation on advisory boards, clinical trials or as speaker for one or more of the following: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Bayer Schering Pharma AG, Biogen IDEC GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Celgene GmbH, Celgene International II Sàrl, Charité Research Organization GmbH, Dr. Willmar Schwabe GmbH & Co. KG, Flexopharm GmbH & Co. KG, Generon Corporation Ltd., Janssen-Cilag GmbH, La Roche-Posay Laboratoire Dermatologique Deutschland, Novartis Pharma GmbH, Parexel International GmbH, Pfizer Deutschland GmbH, Sanofi-Aventis Deutschland GmbH, TFS Trial Form Support GmbH, UCB Pharma GmbH. G.B.E.J. is the vice president and a founding member of the EHSF, a board member of the Nordic Association of Dermatology and an honorary member of the British Association of Dermatologists. G.B.E.J. is also a member of the European Academy of Dermatology and Venereology, the American Academy of Dermatology, the Serbian Association of Dermatovenereologists, the Hungarian Society of Dermatology, the Baltic Association of Dermatovenerologists, the Finnish Society of Dermatology and the Latvian Society of Dermatology and Venereology. G.B.E.J. is the Editor-in-chief of <i>Dermatology</i>, commissioning editor of <i>Clinical Problems in Dermatology</i>, associate editor of <i>Clinical Dermatology</i> and <i>Acta Dermatovenerologica Adriatica, Pannonica et Alpina</i>, and an editorial board member of <i>Acta Dermatovenerologica Croatica</i> and <i>Frontiers in Medicine</i>. G.B.E.J. has received research grants and grants for participation as an investigator from Abbvie, Astra-Zeneca, Inflarx, Janssen-Cilag, Leo Pharma, Novartis, Regeneron and Sanofi. He has also received unrestricted departmental grants from Abbvie, Leo Pharma, and Novartis. G.B.E.J. has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Novartis, Pierre Fabre and UCB for participation on advisory boards, and has received speaker honoraria from AbbVie, Boehringer-Ingelheim, Galderma, MSD and Novartis. Ł.M. is a founding member of the EHSF and a member of the European Academy of Dermatology and Venereology and Polish Dermatological Society. Ł.M. has received research grants, travel grants, consulting honoraria or lecturer’s honoraria from AbbVie, Amgen, Behringer Ingelheim, InfraRX, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Pfizer, Pierre Fabre, Polpharma, Regeneron, Novartis, Trevi, UCB and Valeant. A.B.K. is a consultant and investigator for Novartis, Abbvie, UCB, Pfizer, Lilly and Janssen. A.B.K. has received fellowship funding from Janssen and Abbvie. K.W. has received research grants, travel grants, consulting honoraria or lecturer’s honoraria from AbbVie, Bayer Schering Pharma, Biogen IDEC, Celgene, Dr. Willmar Schwabe GmbH & Co. KG, Flexopharm, Generon Corporation, Janssen-Cilag, Johnson & Johnson, Novartis, Pfizer, Sanofi-Aventis, TFS Trial Form Support and UCB. E.P. declares no competing interests.